DNTH
Dianthus Therapeutics, Inc. /DE/Company with tickers: DNTH
CIK
1690585
CUSIP
252828108
Shares Outstanding
54,666,233
13F Activity (30d)
178 filings
176 filers
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
| Line Item | Value | Unit | Period End | Form | Filed |
|---|---|---|---|---|---|
| Revenue | — | ||||
| Revenue (ASC 606) | — | ||||
| Cost of Revenue | — | ||||
| Gross Profit | — | ||||
| Operating Expenses | $46,996,000 | USD | 2026-03-31 | 10-Q | 2026-05-05 |
| Research & Development | $34,528,000 | USD | 2026-03-31 | 10-Q | 2026-05-05 |
| Operating Income | $-46,533,000 | USD | 2026-03-31 | 10-Q | 2026-05-05 |
| Net Income | $-40,834,000 | USD | 2026-03-31 | 10-Q | 2026-05-05 |
| EPS (Basic) | $-0.85 | USD/shares | 2026-03-31 | 10-Q | 2026-05-05 |
| EPS (Diluted) | $-0.85 | USD/shares | 2026-03-31 | 10-Q | 2026-05-05 |